Heather J. Ribaudo

Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial.

Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S.

Clin Infect Dis. 2021 Jun 16. PMID: 34134131

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.

Hoffmann U, Lu MT, Foldyna B, Zanni MV, Karady J, Taron J, Zhai BK, Burdo T, Fitch KV, Kileel EM, Williams K, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg J, Currier J, Sponseller CA, Melbourne K, Floris-Moore M, Van Dam C, Keefer MC, Koletar SL, Douglas PS, Ribaudo H, Mayrhofer T, Grinspoon SK.

JAMA Netw Open. 2021 Jun 01. 4(6):e2114923. PMID: 34185068

Impact of pre-existing drug resistance on risk of virological failure in South Africa.

Li JZ, Stella N, Choudhary MC, Javed A, Rodriguez K, Ribaudo H, Moosa MY, Brijkumar J, Pillay S, Sunpath H, Noguera-Julian M, Paredes R, Johnson B, Edwards A, Marconi VC, Kuritzkes DR.

J Antimicrob Chemother. 2021 05 12. 76(6):1558-1563. PMID: 33693678

Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

Fichtenbaum CJ, Ribaudo HJ, Leon-Cruz J, Overton ET, Zanni MV, Malvestutto CD, Aberg JA, Kileel EM, Fitch KV, Van Schalkwyk M, Kumarasamy N, Martinez E, Santos BR, Joseph Y, Lo J, Siminski S, Melbourne K, Sponseller CA, Desvigne-Nickens P, Bloomfield GS, Currier JS, Hoffmann U, Douglas PS, Grinspoon SK.

J Infect Dis. 2021 Feb 03. 223(2):352. PMID: 33068427

Effects of HIV Infection on Arterial Endothelial Function: Results From a Large Pooled Cohort Analysis.

Stein JH, Kime N, Korcarz CE, Ribaudo H, Currier JS, Delaney JC.

Arterioscler Thromb Vasc Biol. 2021 01. 41(1):512-522. PMID: 33327750

Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.

Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT.

J Acquir Immune Defic Syndr. 2020 12 15. 85(5):651-658. PMID: 33177476

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

Fichtenbaum CJ, Ribaudo HJ, Leon-Cruz J, Overton ET, Zanni MV, Malvestutto CD, Aberg JA, Kileel EM, Fitch KV, Van Schalkwyk M, Kumarasamy N, Martinez E, Santos BR, Joseph Y, Lo J, Siminski S, Melbourne K, Sponseller CA, Desvigne-Nickens P, Bloomfield GS, Currier JS, Hoffmann U, Douglas PS, Grinspoon SK.

J Infect Dis. 2020 07 09. 222(Suppl 1):S8-S19. PMID: 32645162

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

Smeaton LM, Kileel EM, Grinsztejn B, Gardner EM, Starr K, Murry ML, Desvigne-Nickens P, Alston-Smith B, Waclawiw MA, Cooper-Arnold K, Madruga JV, Sangle S, Fitch KV, Zanni MV, Douglas PS, Ribaudo HJ, Grinspoon SK, Klingman KL.

J Infect Dis. 2020 07 09. 222(Suppl 1):S31-S40. PMID: 32645160

Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.

Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV.

J Infect Dis. 2020 07 09. 222(Suppl 1):S63-S69. PMID: 32645158

Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.

Grinspoon SK, Douglas PS, Hoffmann U, Ribaudo HJ.

J Infect Dis. 2020 07 09. 222(Suppl 1):S1-S7. PMID: 32645161